Edwards Lifesciences Corporation

95.93-1.62-1.66%Vol 2.30M1Y Perf 9.01%
May 16th, 2022 16:00 DELAYED
BID93.12 ASK97.30
Open96.85 Previous Close97.55
Pre-Market- After-Market95.43
 - -  -0.50 -0.52%
Target Price
131.58 
Analyst Rating
Strong Buy 1.32
Potential %
37.16 
Finscreener Ranking
★★★+     51.75
Insiders Trans % 3/6/12 mo.
-100/-96/-98 
Value Ranking
★★★     52.42
Insiders Value % 3/6/12 mo.
-100/-99/-100 
Growth Ranking
★★★★★     71.09
Insiders Shares Cnt. % 3/6/12 mo.
-100/-99/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
19.31 
Earnings Rating
Sell
Market Cap59.64B 
Earnings Date
26th Apr 2022
Alpha0.01 Standard Deviation0.09
Beta1.16 

Today's Price Range

95.7697.91

52W Range

87.36131.73

5 Year PE Ratio Range

31.30102.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.16%
1 Month
-20.07%
3 Months
-10.25%
6 Months
-18.94%
1 Year
9.01%
3 Years
66.24%
5 Years
157.32%
10 Years
596.83%

TickerPriceChg.Chg.%
EW95.93-1.6200-1.66
AAPL145.54-1.5700-1.07
GOOG2 295.85-34.4600-1.48
MSFT261.500.38000.15
XOM90.952.09002.35
WFC42.21-0.4300-1.01
JNJ178.081.23000.70
FB200.041.42000.71
GE74.63-0.4200-0.56
JPM118.26-0.8300-0.70
Financial StrengthValueIndustryS&P 500US Markets
2.30
3.40
0.10
0.12
104.90
Leverage Ratio 1.50
ProfitabilityValueIndustryS&P 500US Markets
76.60
33.20
35.70
27.10
28.70
RevenueValueIndustryS&P 500US Markets
5.36B
8.62
9.48
10.09
Earnings HistoryEstimateReportedSurprise %
Q01 20220.580.603.45
Q04 20210.550.51-7.27
Q03 20210.530.541.89
Q02 20210.550.6416.36
Q01 20210.470.5414.89
Q04 20200.530.50-5.66
Q03 20200.450.5113.33
Q02 20200.150.34126.67
Earnings Per EndEstimateRevision %Trend
6/2022 QR0.64-1.54Negative
9/2022 QR0.650.00-
12/2022 FY2.56-0.39Negative
12/2023 FY2.83-1.74Negative
Next Report Date-
Estimated EPS Next Report0.58
Estimates Count12
EPS Growth Next 5 Years %12.90
Volume Overview
Volume2.30M
Shares Outstanding621.75K
Shares Float616.93M
Trades Count32.71K
Dollar Volume221.32M
Avg. Volume3.07M
Avg. Weekly Volume3.26M
Avg. Monthly Volume3.22M
Avg. Quarterly Volume2.73M

Edwards Lifesciences Corporation (NYSE: EW) stock closed at 95.93 per share at the end of the most recent trading day (a -1.66% change compared to the prior day closing price) with a volume of 2.30M shares and market capitalization of 59.64B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 14900 people. Edwards Lifesciences Corporation CEO is Michael A. Mussallem.

The one-year performance of Edwards Lifesciences Corporation stock is 9.01%, while year-to-date (YTD) performance is -25.95%. EW stock has a five-year performance of 157.32%. Its 52-week range is between 87.36 and 131.73, which gives EW stock a 52-week price range ratio of 19.31%

Edwards Lifesciences Corporation currently has a PE ratio of 40.00, a price-to-book (PB) ratio of 10.38, a price-to-sale (PS) ratio of 11.13, a price to cashflow ratio of 35.70, a PEG ratio of 2.32, a ROA of 20.38%, a ROC of 25.64% and a ROE of 30.29%. The company’s profit margin is 28.70%, its EBITDA margin is 35.70%, and its revenue ttm is $5.36 Billion , which makes it $8.62 revenue per share.

Of the last four earnings reports from Edwards Lifesciences Corporation, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.58 for the next earnings report. Edwards Lifesciences Corporation’s next earnings report date is -.

The consensus rating of Wall Street analysts for Edwards Lifesciences Corporation is Strong Buy (1.32), with a target price of $131.58, which is +37.16% compared to the current price. The earnings rating for Edwards Lifesciences Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Edwards Lifesciences Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Edwards Lifesciences Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 8.35, ATR14 : 4.20, CCI20 : -82.09, Chaikin Money Flow : -0.24, MACD : -5.84, Money Flow Index : 17.91, ROC : -12.61, RSI : 34.36, STOCH (14,3) : 18.25, STOCH RSI : 0.81, UO : 37.29, Williams %R : -81.75), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Edwards Lifesciences Corporation in the last 12-months were: Bernard J. Zovighian (Option Excercise at a value of $0), Daveen Chopra (Option Excercise at a value of $1 086 640), Daveen Chopra (Sold 24 000 shares of value $2 398 989 ), Donald E. Bobo (Option Excercise at a value of $1 679 386), Donald E. Bobo (Sold 73 025 shares of value $8 026 965 ), Huimin Wang (Option Excercise at a value of $1 493 452), Huimin Wang (Sold 61 825 shares of value $6 971 094 ), Jean-Luc M. Lemercier (Option Excercise at a value of $507 443), Jean-Luc M. Lemercier (Sold 23 320 shares of value $2 584 387 ), Katie Szyman (Option Excercise at a value of $2 423 510), Katie Szyman (Sold 115 957 shares of value $12 918 606 ), Kieran T. Gallahue (Option Excercise at a value of $718 880), Kieran T. Gallahue (Sold 32 256 shares of value $3 573 510 ), Larry L. Wood (Option Excercise at a value of $2 337 567), Larry L. Wood (Sold 65 262 shares of value $7 126 507 ), Martha H. Marsh (Option Excercise at a value of $746 436), Martha H. Marsh (Sold 28 722 shares of value $3 104 563 ), Michael A. Mussallem (Option Excercise at a value of $10 520 960), Michael A. Mussallem (Sold 358 500 shares of value $39 525 860 ), Nicholas J. Valeriani (Buy at a value of $168 345), Scott B. Ullem (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
15 (78.95 %)
16 (76.19 %)
15 (78.95 %)
Moderate Buy
2 (10.53 %)
2 (9.52 %)
2 (10.53 %)
Hold
2 (10.53 %)
3 (14.29 %)
2 (10.53 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.32
Strong Buy
1.38
Strong Buy
1.32

Edwards Lifesciences Corporation

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery.

CEO: Michael A. Mussallem

Telephone: +1 949 250-2500

Address: One Edwards Way, Irvine 92614, CA, US

Number of employees: 14 900

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

64%36%

Bearish Bullish

64%36%

Bearish Bullish

60%40%

TipRanks News for EW

Thu, 28 Apr 2022 02:06 GMT Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Exact Sciences (EXAS) and Cochlear Limited (OtherCHEOF)

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 13:56 GMT Analysts Are Bullish on These Healthcare Stocks: Edwards Lifesciences (EW), Beauty Health (SKIN)

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 12:40 GMT Edwards Lifesciences (EW) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

Wed, 27 Apr 2022 12:36 GMT Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Exact Sciences (EXAS) and Mednax (MD)

- TipRanks. All rights reserved.

Thu, 31 Mar 2022 16:08 GMT Edwards Lifesciences: Solid Business, Room to Improve

- TipRanks. All rights reserved.

Fri, 25 Feb 2022 09:42 GMT Edwards Lifesciences Updates 1 Key Risk Factor

- TipRanks. All rights reserved.

Fri, 28 Jan 2022 09:08 GMT Wall Street Analysts Are Neutral on Top Healthcare Picks

- TipRanks. All rights reserved.

Thu, 27 Jan 2022 16:38 GMT Edwards Lifesciences (EW) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Thu, 27 Jan 2022 12:30 GMT Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW) and Anthem (ANTM)

- TipRanks. All rights reserved.

Fri, 07 Jan 2022 16:34 GMT Morgan Stanley Believes Edwards Lifesciences (EW) Still Has Room to Grow

- TipRanks. All rights reserved.

News

Stocktwits